Prelude Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Prelude Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-135,854	Closed	-$15.7M	–	1493
2023 Q3	$15.7M	Buy	135,854 +27,159	+25%	+$2.92M	1.02%	9
2023 Q2	$11.2M	Sell	108,695 -43,634	-29%	-$4.6M	0.73%	13
2023 Q1	$16.6M	Buy	152,329 +79,596	+109%	+$8.8M	1%	10
2022 Q4	$8.28M	Buy	72,733 +63,245	+667%	+$5.25M	0.43%	28
2022 Q3	$587K	Sell	9,488 -10,305	-52%	-$720K	0.02%	592
2022 Q2	$1.58M	Buy	19,793 +13,478	+213%	+$1.28M	0.04%	372
2022 Q1	$664K	Buy	+6,315	New	+$615K	0.02%	734
2021 Q4	–	Sell	-10,982	Closed	-$1.2M	–	2451
2021 Q3	$1.2M	Buy	10,982 +3,198	+41%	+$332K	0.03%	484
2021 Q2	$729K	Buy	7,784 +5,324	+216%	+$490K	0.02%	766
2021 Q1	$226K	Sell	2,460 -3,260	-57%	-$275K	0.01%	1278
2020 Q4	$418K	Buy	+5,720	New	+$425K	0.01%	784
2020 Q2	–	Sell	-10,768	Closed	-$319K	–	2406
2020 Q1	$319K	Buy	+10,768	New	+$364K	0.02%	372
2019 Q4	–	Sell	-184	Closed	-$5K	–	2451
2019 Q3	$5K	Buy	+184	New	+$4.76K	﹤0.01%	1574
2019 Q2	–	Sell	-275	Closed	-$7K	–	2368
2019 Q1	$7K	Buy	+275	New	+$6.52K	﹤0.01%	1613
2017 Q4	–	Sell	-1,700	Closed	-$22K	–	1898
2017 Q3	$22K	Buy	+1,700	New	+$21.6K	﹤0.01%	1306
2017 Q2	–	Sell	-40,000	Closed	-$591K	–	1994
2017 Q1	$591K	Sell	40,000 -300	-0.7%	-$4.86K	0.06%	317
2016 Q4	$652K	Buy	40,300 +22,000	+120%	+$399K	0.08%	274
2016 Q3	$332K	Buy	+18,300	New	+$358K	0.03%	407
2016 Q1	–	Sell	-10,800	Closed	-$234K	–	1669
2015 Q4	$234K	Buy	+10,800	New	+$210K	0.04%	489
2015 Q3	–	Sell	-2,800	Closed	-$97K	–	1935
2015 Q2	$97K	Buy	+2,800	New	+$85.4K	0.01%	900
2014 Q3	–	Sell	-2,000	Closed	-$32K	–	2265
2014 Q2	$32K	Buy	+2,000	New	+$28.5K	﹤0.01%	1627

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's HZNP Position: Q4 2023 in Review

Prelude Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 135,854 shares — an estimated $15.7M sold.

Prelude Capital Management first reported a position in HZNP in Q2 2014 and held it in 21 quarters. The position peaked at $16.6M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Prelude Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Prelude Capital Management sold 135,854 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $15.7M.
Prelude Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 21 quarters.
Prelude Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $16.6M in Q1 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.